Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients with cystic fibrosis and F508del/F508del-CFTR: patient-reported outcomes in a Phase 3, randomised, controlled trial (EVOLVE)

Autor:	JS Elborn, O Sommerburg, X You, Y Yang, R Rendas-Baum, M Kosinski, B Loop, J Lekstrom-Himes, AA Rizio
Rok vydání:	2019
Předmět:	medicine.medical_specialty business.industry medicine.disease Cystic fibrosis law.invention Ivacaftor Randomized controlled trial law Internal medicine medicine Tezacaftor F508del cftr In patient business medicine.drug
Zdroj:	60. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V..
ISSN:	1438-8790
DOI:	10.1055/s-0039-1678165
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::15df56e028ae97884c59a2c565588bc2 https://doi.org/10.1055/s-0039-1678165 Zobrazit plný text záznamu